Processa Pharmaceuticals, Inc.
Company Snapshot: Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
- Jan 4 2023 Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
- Dec 14 2022 Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
- Nov 8 2022 Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
- Nov 8 2022 PCS12852 Improves Gastric Emptying in Gastroparesis Patients